

Tomato juice consumption reduces systemic inflammation in overweight and obese females

Mahsa Ghavipour¹, Ahmad Saedisomeolia^{1*}, Mahmoud Djalali¹, Giti Sotoudeh¹,
Mohammad Reza Eshraghyan², Ali Malekshahi Moghadam³ and Lisa G. Wood⁴

¹Department of Nutrition and Biochemistry, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

²Department of Epidemiology and Statistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

³Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

⁴School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW 2308, Australia

(Submitted 20 January 2012 – Final revision received 8 June 2012 – Accepted 9 August 2012 – First published online 15 October 2012)

Abstract

Tomatoes are the richest source of lycopene, a potent antioxidant. Tomato products improve antioxidant defences and reduce the risk of inflammatory diseases, at least partly, due to the presence of lycopene. Lycopene, as an anti-inflammatory agent, prevents the production of inflammatory cytokines. Obesity is a chronic inflammatory condition in which the increased level of body fat leads to an increase in circulating inflammatory mediators. We hypothesised that the consumption of a lycopene-rich food would reduce inflammation in people who are overweight or obese. A total of 106 overweight or obese female students of the Tehran University of Medical Sciences were enrolled and randomly allocated to an intervention group (*n* 53) or a control group (*n* 53) consuming 330 ml/d of tomato juice or water, respectively, for 20 d. At baseline and day 20, serum concentrations of IL-6, IL-8, high-sensitivity C-reactive protein and TNF- α were analysed by ELISA and compared between the groups. Serum concentrations of IL-8 and TNF- α decreased significantly in the intervention group compared with the control group and with baseline. Subgroup analysis indicated that this effect was confined to subjects who were overweight. Among obese subjects, serum IL-6 concentration was decreased in the intervention group compared with the control group, with no differences in IL-8 and TNF- α observed. Tomato juice reduces inflammation in overweight and obese females. Thus, increasing tomato intake may provide a useful approach for reducing the risk of inflammatory diseases such as CVD and diabetes, which are associated with obesity.

Key words: Tomato juice: Carotenoids: Lycopene: Inflammatory biomarkers: Obesity

The prevalences of overweight and obesity are continuing to increase in developed as well as developing countries⁽¹⁾. Obesity leads to a state of chronic, low-grade inflammation⁽²⁾, characterised by increased levels of circulating inflammatory biomarkers including C-reactive protein (CRP), TNF- α and IL-6⁽³⁾. This chronic inflammatory state is believed to contribute to the pathophysiology of a wide range of life-threatening diseases, such as CVD, diabetes and cancer⁽⁴⁾. Hence, therapeutic strategies that target obesity-induced inflammation have the potential to greatly reduce disease burden.

Carotenoids are a class of non-enzymatic fat-soluble antioxidants⁽⁵⁾ that can be found in tomatoes and tomato products⁽⁶⁾. Lycopene is the most potent antioxidant among the carotenoids and protects the body from oxidative stress by scavenging free radicals⁽⁷⁾. Lycopene also acts as an anti-inflammatory agent^(8,9). Antioxidants, such as lycopene,

inhibit the activation of NF- κ B, thereby reducing expression of inflammatory cytokines such as IL-6 and IL-8^(10,11). Lycopene also acts in human adipose tissue⁽¹²⁾, on cytokine pathways and reduces the production of inflammatory biomarkers⁽¹³⁾. Therefore, lycopene has the potential to alleviate the damaging effects of obesity-induced inflammation.

There are limited clinical data regarding the effects of tomato juice, or more specifically lycopene, on inflammation in obese or overweight individuals. We hypothesised that the consumption of a lycopene-rich food would reduce inflammation in people who are overweight or obese. The aim of the present study was to determine the effect of tomato juice consumption on the level of inflammatory biomarkers (IL-6, IL-8, high-sensitivity CRP and TNF- α) in overweight and obese female students of the Tehran University of Medical Sciences.

Abbreviation: CRP, C-reactive protein.

* **Corresponding author:** A. Saedisomeolia, email a_saedi@tums.ac.ir

Experimental methods

Study population

A total of 106 overweight or obese female students were recruited from the Tehran University of Medical Sciences via advertisement. Participants were aged between 20 and 40 years and had a BMI of 25 kg/m² or higher. Exclusion criteria were inflammatory diseases, including diabetes, CVD, multiple sclerosis, rheumatoid arthritis, cancers, asthma and allergies, smoking and daily usage of any anti-inflammatory drugs such as aspirin or vitamin/mineral supplements. The present study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects/patients were approved by the Ethics Committee of Human Experimentation of Tehran University of Medical Sciences (no. 10492). Written informed consent was obtained from all subjects/patients.

Study design

Subjects were randomly allocated to the intervention or control group. The group allocation for subjects was determined by computer-generated random allocation, derived and held by an independent statistician. Initial diet allocation was concealed from the clinical recruitment staff until each subject had entered the trial and received a randomisation code. Neither participants nor investigators were blinded to the treatment allocation. The intervention group (*n* 53) and control group (*n* 53) received 330 ml of tomato juice (Takdaneh Company) and water daily for 20 d, respectively. The tomato juice provided 37.0 mg lycopene. Subjects were asked to consume the juice with their main meals (110 ml, three times a day = 330 ml). Subjects were advised to maintain their usual diet and physical activity levels. Analysis of background diet indicated that participants were consuming between one and three tomatoes (average two) and one to three other vegetables and up to two fruit servings daily. The average background lycopene intake of participants was 8.2 (SEM 1.2) mg/d. Adherence to the study was maintained by using telephone calls every 3 d.

Participant flow

A total of 106 subjects were recruited for the study. No adverse events were reported. In the intervention group, all the fifty-three subjects completed the trial and in the control group, fifty-one of the fifty-three subjects completed the study. The progress of subjects through the trial is described in Fig. 1.

Clinic visits

Subjects visited the clinic at baseline and at day 20. At each visit, height and weight were measured (Seca) and BMI was calculated by dividing weight (kg) by height² (m²). Blood (10 ml) was collected at baseline and at day 20. Samples were centrifuged at 3000 g for 10 min at 4°C. Serum was separated and frozen at -70°C in an ultra-freezer (Sanyo) until analysis.




Fig. 1. Study plan.

Biochemical analysis

Serum concentrations of IL-6, IL-8 and TNF- α were measured using commercial ELISA kits (Bender MedSystems Diagnostics GmbH) according to the manufacturer's instructions. High-sensitivity CRP was measured using the turbidometry method (Roche).

Dietary assessments

At baseline and at day 20, dietary intake was estimated using three 24-h food recalls (two working days and one weekend day) (Table 2). The intakes of energy and macronutrients were estimated using Food Processor II Software (ESHA Research). Carotenoid intake (α -carotene, β -carotene, lutein, zeaxanthin and lycopene) was estimated at baseline and at day 20 using a FFQ. Values were converted to mg per d using manual calculations compared to standard tables of the United States Department of Agriculture–Nutrition Coordinating Center Carotenoid Database for US Foods.

Statistical analysis

The Statistical Package for Social Sciences (SPSS) (version 16 for windows; SPSS, Inc.) was used to compare variables at baseline and at day 20 (paired *t* test), as well as the change variables between the two groups (independent *t* test). The Kolmogorov–Smirnov test confirmed that the data were normally distributed. In order to observe the relationship between independent and dependent variables, covariance analysis was performed. *P* values < 0.05 were considered as statistically significant. Values were presented as mean values with their standard errors. Pearson's correlation coefficients were used to examine associations between change variables.

Results

Baseline characteristics were similar for subjects who were randomised to the control *v.* the intervention groups (Table 1). There were also no differences in serum levels of IL-6, IL-8, high-sensitivity CRP and TNF- α between the two groups at baseline (Table 1). Analysis of dietary records indicated that there was no difference between the groups in dietary intake at baseline (Table 2). There were also no changes in dietary intake of nutrients at day 20, compared with baseline,

Table 1. Subject characteristics at baseline
(Mean values with their standard errors)

Variables	Intervention group (n 53)		Control group (n 53)		P
	Mean	SEM	Mean	SEM	
Age (years)	23.3	0.5	23.2	0.4	0.858
Height (cm)	159.9	0.8	159.6	0.9	0.861
Weight (kg)	71.8	1.3	72.4	1.1	0.740
BMI (kg/m ²)	28.2	0.3	28.3	0.3	0.814
IL-6 (pg/ml)	69.3	2.4	68.3	1.7	0.736
IL-8 (pg/ml)	129.2	1.8	127.5	1.4	0.476
hsCRP (mg/l)	15.4	4.1	15.7	2.9	0.954
TNF- α (pg/ml)	72.3	12.7	66.7	11.9	0.749

hsCRP, high-sensitivity C-reactive protein.

in either group (Table 2). Following the treatment phase, in the intervention group, tomato juice consumption led to significantly decreased serum concentrations of TNF- α and IL-8 compared with baseline and with control group (Table 3). In the control group, there was an increase in TNF- α and IL-8 concentrations compared with baseline (Table 3). Additional subgroup analysis was performed, with subjects classified as overweight or obese, according to their baseline BMI. In the overweight intervention group, serum concentrations of TNF- α and IL-8 decreased compared with baseline and with overweight control group (Table 3). Among obese subjects, serum IL-6 concentration was decreased in the intervention group compared with the control group, with no differences in IL-8, high-sensitivity CRP and TNF- α observed (Table 3).

Discussion

The present study is the first to demonstrate that tomato juice reduces systemic inflammation in overweight and obese females. Following supplementation, we observed that tomato juice significantly decreased serum concentrations of IL-8 and TNF- α . Subgroup analysis demonstrated that subjects

who were overweight were more responsive to the effects of the tomato juice, with decreases in serum concentrations of TNF- α and IL-8, while obese subjects showed a decrease in serum IL-6 concentration.

The results that we observed in the present study are in general agreement with a study by Riso *et al.*⁽¹⁴⁾, which showed modest effects on the production of inflammatory mediators, such as TNF- α , following the regular intake of a tomato drink by young healthy volunteers. Similarly, Watzl *et al.*⁽¹⁵⁾ demonstrated that the highest production of TNF- α was associated with a low lycopene intake. Hazewindus *et al.*⁽¹⁶⁾ in their study on lycopene, ascorbic acid and α -tocopherol, also found that lycopene considerably diminished inflammation by suppressing the release of TNF- α and stimulating IL-10 production. Cell culture⁽⁹⁾ as well as experimental studies⁽¹⁷⁾ also reported similar findings. *In vitro*⁽⁹⁾, lycopene decreased the release of IL-6 and interferon-induced protein of 10 kDa by airway epithelial cells following exposure to lipopolysaccharide. It has also been shown that lycopene reduced oxysterol-induced pro-inflammatory cytokine (IL-1 β , IL-6, IL-8 and TNF- α) production and expression in human macrophages⁽¹⁸⁾. *Ex vivo* studies revealed that inflammatory biomarkers such as IL-6, monocyte chemoattractant protein-1 and IL-1 β decreased (at both the mRNA and protein level) when epididymal adipose tissue of mice was incubated with lycopene⁽¹⁹⁾. The same effect was reported when adipose tissue was pre-incubated with lycopene and then stimulated using TNF- α ⁽¹⁹⁾. Likewise, Gouranton *et al.*⁽¹⁹⁾ reported similar findings with human adipocyte primary cultures. In a clinical setting⁽¹⁷⁾, lycopene and tomato extract inhibited non-alcoholic steatohepatitis-promoted hepatocarcinogenesis, mainly as a result of reduced oxidative stress, which could modify various pathways involved in carcinogenesis.

The nature of obesity as a chronic inflammatory condition⁽²⁰⁾ highlights the potential beneficial role of nutrients such as lycopene, which have anti-inflammatory properties. As the level of inflammation increases with increasing BMI, we expected that obese subjects would experience a greater

Table 2. Dietary intake at baseline and change in dietary intake between baseline and day 20, in the intervention and control groups

(Mean values with their standard errors)

Daily intake	Intervention group (n 53)				Control group (n 53)			
	Baseline		Change at day 20		Baseline		Change at day 20	
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM
Total energy								
kcal	1332.2	50.3	4.52	2.27	1228.7	36.7	0.14	0.23
kJ	5573.6	210.4	18.9	9.5	5140.9	153.6	0.59	0.96
Protein (%)*	14.3	0.5	-0.05	0.08	15.5	0.8	0.23	0.13
Carbohydrate (%)*	54.0	1.0	0.16	0.14	54.5	1.0	-0.11	0.06
Fat (%)*	31.6	0.9	0.11	0.07	29.9	0.4	0.05	0.03
β -Carotene (μ g)	731.3	71.6	-0.02	0.11	736.3	74.3	0.02	0.23
α -Carotene (μ g)	1.8	0.2	0.01	0.01	1.8	0.3	-0.01	0.01
Lutein + zeaxanthin (μ g)	44.0	3.7	0.008	0.02	44.8	3.8	0.009	0.02
Lycopene (μ g)	8156.9	1226.1	1.75	1.99	8215.5	1267.1	0.01	0.21

*Percentage of energy derived from each nutrient. There were no differences in baseline values between the control and the intervention groups. There were also no differences in the change in dietary intake between baseline and day 20 and between the control and intervention groups.

Table 3. Change in systemic inflammatory markers between baseline and day 20, in the intervention and control groups (Mean values with their standard errors)

Variables	Combined obese and overweight				Overweight				Obese				
	Intervention group (n 53)		Control group (n 51)		Intervention group (n 43)		Control group (n 42)		Intervention group (n 10)		Control group (n 9)		P
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	
IL-6 (pg/ml)	-0.18	1.18	1.94	2.03	0.60	1.32	1.48	2.44	-3.60	2.41	4.06	1.87	0.024
IL-8 (pg/ml)	-9.91*	2.22	6.39*	1.95	-11.77*	2.58	6.22*	2.17	-1.88	2.89	7.21	4.57	0.104
TNF- α (pg/ml)	-8.25*	3.01	0.08*	0.02	-5.24*	1.58	0.07*	0.02	21.2	14.30	0.14	0.08	0.176
hsCRP (mg/l)	5.00	3.85	2.81	1.86	5.46	4.70	2.27	1.66	3.03	3.17	5.37	7.43	0.767

hsCRP, high-sensitivity C-reactive protein.

*Mean values were significantly different for day 20 compared to baseline ($P < 0.05$).

improvement in inflammation than the overweight subjects, following the tomato juice intervention, because higher fat mass leads to increased inflammation⁽²¹⁾. However, subgroup analysis, with subjects classified according to their baseline BMI, determined that daily tomato juice consumption had a more pronounced effect in the overweight subjects. Indeed, there were decreases in the serum concentrations of both IL-8 and TNF- α in overweight subjects. In obese subjects, only serum concentration of IL-6 was decreased by tomato juice consumption. It is unclear why more significant changes were seen in the overweight, compared with the obese, group. It is possible that the anti-inflammatory actions of lycopene were not potent enough to dampen the heightened level of baseline inflammation that was present in the obese group. Alternatively, this observation may be due to study limitations. There was a disparity in the number of subjects in the overweight *v.* obese groups (overweight group, *n* 85 *v.* obese group, *n* 19). Hence, the obese group may have been underpowered to detect changes in other inflammatory mediators.

The anti-inflammatory effects that we observed may be attributable to the presence of lycopene in the tomato juice⁽²²⁾. Studies have shown that lycopene decreases the translocation of NF- κ B, which leads to a decreased expression of inflammatory biomarkers including IL-8 as well as TNF- α ⁽²³⁾. This anti-inflammatory effect of lycopene is related to its redox property⁽¹¹⁾. Many studies have shown that lycopene decreases the translocation of NF- κ B, via activation of I- κ B, which is an inhibitor of NF- κ B^(18,24). Regarding the molecular mechanism, Gouranton *et al.*⁽¹⁹⁾ showed that the presence of lycopene suppresses the luciferase gene reporter under control of the NF- κ B-responsive element. Furthermore, the involvement of the NF- κ B pathway was shown by the modulation of I κ kinase α/β phosphorylation by lycopene. Tomato juice also contains other important nutrients including the antioxidants β -carotene and vitamin C. β -Carotene⁽²⁵⁾ and vitamin C⁽²⁶⁾ have been shown to decrease inflammation via their probable redox-based effect on inactivation of NF- κ B. The individual effects of these other nutrients cannot be determined by the present study, but it is likely that they have also contributed to the anti-inflammatory effects (via their redox action) that we have observed. This highlights the benefit of supplementing with whole foods, rather than with individual nutrients, in order to maximise the benefits of nutritional interventions, a fact that has been shown by other researchers^(27,28). We conclude that tomato juice reduces the inflammatory mediators that are associated with overweight and obesity in females. Thus, increasing tomato intake may provide a useful approach for reducing the risk of inflammatory diseases, such as CVD and diabetes, which are associated with obesity.

Acknowledgements

The authors gratefully acknowledge the students and officials of Kooy and Vesal dormitories for their sincere cooperation. The present work was supported by the Vice-chancellor for Research of Tehran University of Medical Sciences (grant no. 10492), and the authors declare no conflict of interests. The authors would like to advise that all authors listed have

contributed to the work. M. G. recruited the patients and collected the samples, performed laboratory tests, analysed the data and drafted the manuscript. A. S., G. S. and L. G. W. supervised the nutrition science experiments, contributed to the study design and reviewed the manuscript. M. D. supervised the biochemical experiments and contributed to the writing of the manuscript. M. R. E. contributed to the data analysis and the interpretation of results. A. M. M. performed laboratory tests and contributed to the writing of the manuscript.

References

1. Das UN (2010) Obesity: genes, brain, gut, and environment. *Nutrition* **26**, 459–473.
2. Das UN (2002) Obesity, metabolic syndrome X, and inflammation. *Nutrition* **18**, 430–432.
3. Luc G, Bard JM, Juhan-Vague I, *et al.* (2003) C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. *Arterioscler Thromb Vasc Biol* **23**, 1255–1261.
4. Das UN (2006) Aberrant expression of perilipins and 11-beta-HSD-1 as molecular signatures of metabolic syndrome X in south east Asians. *J Assoc Physicians India* **54**, 637–649.
5. El-Agamey A, Lowe GM, McGarvey DJ, *et al.* (2004) Carotenoid radical chemistry and antioxidant/pro-oxidant properties. *Arch Biochem Biophys* **430**, 37–48.
6. Canene-Adams K, Campbell JK, Zaripheh S, *et al.* (2005) The tomato as a functional food. *J Nutr* **135**, 1226–1230.
7. Chaiyasit W, McClements DJ & Decker EA (2005) The relationship between the physicochemical properties of antioxidants and their ability to inhibit lipid oxidation in bulk oil and oil-in-water emulsions. *J Agric Food Chem* **53**, 4982–4988.
8. Bignotto L, Rocha J, Sepodes B, *et al.* (2009) Anti-inflammatory effect of lycopene on carrageenan-induced paw oedema and hepatic ischaemia–reperfusion in the rat. *Br J Nutr* **102**, 126–133.
9. Saedisomeolia A, Wood LG, Garg ML, *et al.* (2009) Lycopene enrichment of cultured airway epithelial cells decreases the inflammation induced by rhinovirus infection and lipopolysaccharide. *J Nutr Biochem* **20**, 577–585.
10. Kim J, Sanders SP, Siekierski ES, *et al.* (2000) Role of NF-kappa B in cytokine production induced from human airway epithelial cells by rhinovirus infection. *J Immunol* **165**, 3384–3392.
11. Kim GY, Kim JH, Ahn SC, *et al.* (2004) Lycopene suppresses the lipopolysaccharide-induced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen-activated protein kinases and nuclear factor-kappaB. *Immunology* **113**, 203–211.
12. Walfish Y, Walfish S, Agbaria R, *et al.* (2000) Lycopene in serum, skin and adipose tissues after tomato-oleoresin supplementation in patients undergoing haemorrhoidectomy or peri-anal fistulotomy. *Br J Nutr* **90**, 759–766.
13. Herzog A, Siler U, Spitzer V, *et al.* (2005) Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. *FASEB J* **19**, 272–274.
14. Riso P, Visioli F, Grande S, *et al.* (2006) Effect of a tomato-based drink on markers of inflammation, immunomodulation, and oxidative stress. *J Agric Food Chem* **54**, 2563–2566.
15. Watzl B, Bub A, Briviba K, *et al.* (2003) Supplementation of a low-carotenoid diet with tomato or carrot juice modulates immune functions in healthy men. *Ann Nutr Metab* **47**, 255–261.
16. Hazewindus M, Haenen GRMM, Weseler AR, *et al.* (2012) The anti-inflammatory effect of lycopene complements the antioxidant action of ascorbic acid and α -tocopherol. *Food Chem* **132**, 954–958.
17. Wang Y, Ausman LM, Greenberg AS, *et al.* (2010) Dietary lycopene and tomato extract supplementations inhibit non-alcoholic steatohepatitis-promoted hepatocarcinogenesis in rats. *Int J Cancer* **126**, 1788–1796.
18. Palozza P, Simone R, Catalano A, *et al.* (2011) Lycopene prevention of oxysterol-induced proinflammatory cytokine cascade in human macrophages: inhibition of NF-kappaB nuclear binding and increase in PPARGamma expression. *J Nutr Biochem* **22**, 259–268.
19. Gouranton E, Thabuis C, Riollet C, *et al.* (2011) Lycopene inhibits proinflammatory cytokine and chemokine expression in adipose tissue. *J Nutr Biochem* **22**, 642–648.
20. Eckel RH (1997) Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee. American Heart Association. *Circulation* **96**, 3248–3250.
21. Mehta S & Farmer JA (2007) Obesity and inflammation: a new look at an old problem. *Curr Atheroscler Rep* **9**, 134–138.
22. Maruyama C, Imamura K, Oshima S, *et al.* (2001) Effects of tomato juice consumption on plasma and lipoprotein carotenoid concentrations and the susceptibility of low density lipoprotein to oxidative modification. *J Nutr Sci Vitaminol (Tokyo)* **47**, 213–221.
23. Blackwell TS & Christman JW (1997) The role of nuclear factor-kappa B in cytokine gene regulation. *Am J Respir Cell Mol Biol* **17**, 3–9.
24. Huang CS, Fan YE, Lin CY, *et al.* (2007) Lycopene inhibits matrix metalloproteinase-9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1. *J Nutr Biochem* **18**, 449–456.
25. Bai SK, Lee SJ, Na HJ, *et al.* (2005) Beta-carotene inhibits inflammatory gene expression in lipopolysaccharide-stimulated macrophages by suppressing redox-based NF-kappaB activation. *Exp Mol Med* **37**, 323–334.
26. Cindrova-Davies T, Spasic-Boskovic O, Jauniaux E, *et al.* (2007) Nuclear factor-kappa B, p38, and stress-activated protein kinase mitogen-activated protein kinase signaling pathways regulate proinflammatory cytokines and apoptosis in human placental explants in response to oxidative stress: effects of antioxidant vitamins. *Am J Pathol* **170**, 1511–1520.
27. Basu A & Imrhan V (2007) Tomatoes versus lycopene in oxidative stress and carcinogenesis: conclusions from clinical trials. *Eur J Clin Nutr* **61**, 295–303.
28. Shi J, Kakuda Y & Yeung D (2004) Antioxidative properties of lycopene and other carotenoids from tomatoes: synergistic effects. *Biofactors* **21**, 203–210.